What is the recommended evaluation and management for a 50-year-old perimenopausal woman with elevated sex hormone‑binding globulin (SHBG) and low dehydroepiandrosterone sulfate (DHEA‑S)?

Evaluation and Management of High SHBG with Low DHEA-S in a Perimenopausal Woman

In a 50-year-old perimenopausal woman with markedly elevated SHBG (199.0 nmol/L) and low DHEA-S (38.4 μg/dL), the priority is to identify the underlying cause of the elevated SHBG rather than treating the low DHEA-S, as routine DHEA supplementation is not recommended for women with low androgen levels.

Initial Diagnostic Approach

Identify Causes of Elevated SHBG

The SHBG level of 199.0 nmol/L is substantially elevated (typically normal range 20-80 nmol/L for women). This requires immediate investigation for:

• Hyperthyroidism - Check TSH and free T4 1
• Liver disease - Obtain liver function tests (AST, ALT, bilirubin, albumin) 1
• Medications with estrogenic effects - Review current medications, particularly:
  • Tamoxifen
  • Raloxifene
  • Oral estrogen replacement therapy 1

Critical point: Elevated SHBG can create a misleading picture where total testosterone appears normal or even elevated, but bioavailable testosterone is actually low due to excessive binding 1. This is the opposite of typical perimenopause.

Assess DHEA-S in Context

The DHEA-S level of 38.4 μg/dL represents an age-appropriate decline. DHEA-S naturally decreases by approximately 80% from age 20 to 80, with a 2-3% annual decline during the perimenopausal transition 2. For a 50-year-old woman, values in the 35-150 μg/dL range are expected 3.

Complete Hormonal Assessment

Obtain fasting morning blood samples (days 1-7 of cycle if still menstruating) for:

• Total testosterone - First-line androgen assessment 1
• Free or bioavailable testosterone - Essential given the elevated SHBG 4
• Free Androgen Index (FAI) - Calculated as (Total T/SHBG) × 100, provides functional androgen status 2
• Estradiol - To assess menopausal status
• LH and FSH - Confirm perimenopausal state 4

The free testosterone or FAI is critical here - with SHBG this elevated, total testosterone measurements alone are meaningless 1, 5.

Management Strategy

Do NOT Routinely Supplement DHEA

The 2014 Endocrine Society guideline explicitly recommends against routine DHEA supplementation in women with low androgen levels 6. This applies even in the setting of:

• Adrenal insufficiency (unless specific symptoms present)
• Surgical menopause
• Natural menopause
• Hypopituitarism

The evidence shows:

• Limited data supporting symptom improvement 6
• No long-term safety data 6
• Lack of well-defined androgen deficiency syndrome in healthy women 6

Consider DHEA Only in Specific Circumstances

DHEA supplementation (25-50 mg daily) may be considered only if 7, 8:

1. Adrenal insufficiency is present with documented low libido, depression, or low energy despite optimized glucocorticoid replacement
2. Trial period: 6 months maximum
3. Discontinue if no sustained benefit after 6 months 7
4. Monitor: Morning DHEA-S levels (aim for mid-normal range) 7

Address the Elevated SHBG

This is the primary therapeutic target:

1. If hyperthyroidism: Treat thyroid disorder - SHBG will normalize with euthyroid state
2. If liver disease: Address underlying hepatic pathology
3. If medication-induced:
   • Consider switching oral estrogen to transdermal (if on HRT)
   • Reassess need for SERMs if applicable
4. If no identifiable cause: The elevated SHBG may be reducing androgen bioavailability, creating functional androgen deficiency despite normal total testosterone 5

Symptom-Directed Management

For sexual dysfunction (if present):

• The 2014 Endocrine Society guideline supports short-term testosterone therapy for postmenopausal women with hypoactive sexual desire disorder 6
• However, endogenous testosterone levels do not predict response 6
• Physiological testosterone preparations are not FDA-approved in the US 6
• Monitor for androgen excess if prescribed 6

For metabolic concerns:

• Lower SHBG typically associates with metabolic syndrome, but elevated SHBG (as in this case) may indicate different pathophysiology 2
• Screen for cardiovascular risk factors regardless 4

Common Pitfalls to Avoid

1. Do not interpret total testosterone in isolation when SHBG is abnormal - always calculate free testosterone or FAI 1, 5

2. Do not assume low DHEA-S requires treatment - age-appropriate decline is physiologic 2

3. Do not prescribe DHEA as a "dietary supplement" without specific indications and monitoring 6, 7

4. Do not overlook thyroid disease - this is the most common reversible cause of markedly elevated SHBG 1

5. Recognize that perimenopausal women typically have declining SHBG (due to declining estradiol), so an elevated SHBG is paradoxical and demands explanation 2, 9

Follow-Up

• Reassess after treating underlying SHBG elevation
• Repeat hormonal panel in 3 months if intervention implemented
• If DHEA trial initiated, formal reassessment at 6 months with discontinuation if ineffective 7